NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3235 participants.

Also called NCT01303640

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,235 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01303640
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01303640. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
Acronym
NEXT
Intervention (Device)
Biolimus-eluting stent
Intervention (Device)
Everolimus-eluting stent
Lead sponsor
Takeshi Morimoto (class: other)

Record details

Record id
cardio:ct-nct01303640
Content hash
b1b855eaaa66cd796adc7b00bf39d36ca38878d690fab14f0b3d72ae74f7c6d5